Novo Nordisk Seeks To Halt Sanofi Insulin Pen
Novo Nordisk filed a motion for a preliminary injunction on Monday that would prevent Sanofi-Aventis and its U.S. affiliate from making and selling SoloStar in the U.S. until the conclusion of its patent infringement case.
Denmark-based drug-maker Novo says SoloStar is threatening its market share for pens and long-lasting insulin.
“Prompt resolution of Novo’s motion for preliminary injunction is essential here because the importation, sale, and...
To view the full article, register now.